A Multi-disciplinary Team Approach to the Management of Squamous Cell Carcinoma Wounds Supported by Bioactive Microfibre Gelling (BMG™) Technology


Squamous cell carcinoma (SCC) of the skin is the second most common form of skin cancer, characterised by abnormal, accelerated growth of squamous cells. SCC occurs when DNA damage from exposure to ultraviolet radiation or other damaging agents trigger changes in the squamous cells. SCCs can appear as scaly red patches, open erosions, rough, thickened or raised growths with a central depression. Untreated SCCs can become invasive, grow into deeper layers of skin and spread to other parts of the body (Venables et al 2013-2015).

As a multidisciplinary team we set out to evaluate an innovative Bioactive Microfibre (BMG™) dressing (MaxioCel®) in the management of post excision SCC wounds.


Case study series of two post excision wounds, with BMG dressing (MaxioCel) to reduce wound overgranulation, manage wound exudate, reduce odour and facilitate effective wound bed management.


  • Non healing wound of a year’s duration, a vast improvement was observed, after just 2.5 weeks of
    treatment leading to 100% granulation and almost complete closure at 6 weeks.
  • Overall reduction in wound size and reduction of over-granulation observed.
  • Managed biofilm and exudate. No adherence to wound bed. Medical Imagery supports these results.

Change in average condition of wound bed over 3 weeks.


Case Study

An 84-year-old male presented with a non-healing wound post-excision of Squamous Cell Carcinoma on the scalp. The wound was 100% over-granulated and had been present for over a year.

Previous treatments included various primary and secondary dressings without success.

The introduction of MaxioCel® as a primary dressing with a biofilm treatment pathway led to significant improvements. Within 2.5 weeks, the wound had markedly improved, with the patient and clinician expressing high satisfaction with the results. The wound was nearly healed after 6 weeks of MaxioCel treatment, leading to its consideration for the specialist formulary due to its effectiveness and potential health economic benefits.

Before and after photos of Squamous cell carcinoma to the scalp.

“MaxioCel allowed full visibility of the wound bed in all cases and exceeded clinical expectations.


Working in partnership with the Skin Integrity Team, the treatment aims were achieved. MaxioCel allowed full visibility of the wound bed in all cases and exceeded clinical expectations. Patient clinic visits reduced. Patients’ wounds in this case study series are now better managed and the patients reported being more comfortable. We are now considering the inclusion of MaxioCel onto the specialist wound care formulary.

To see the full poster, presented at Wound Care Today 2024, including more details on the case study highlighted, download below.

Download PDF


Venables, Z C et al. “Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013-15: a cohort study.” The British journal of dermatology vol. 181,3 (2019): 474-482. doi:10.1111/bjd.17873